{"url_path":"/sec/ctso/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-060270-index.html","accession_number":"0001104659-26-060270","cik":"0001175151","ticker":"CTSO","issuer_name":"Cytosorbents Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1175151/0001104659-26-060270-index.html","primary_entity_key":"0001175151","primary_entity_name":"Cytosorbents Corp"},"word_count":309,"has_tables":true,"body_markdown":"**Item 6. Exhibits.**\n\n​\n\nNumber\n\n  ​ ​ ​\n\nDescription\n\n31.1*\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.](ctso-20260331xex31d1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.](ctso-20260331xex31d2.htm)\n\n32.1**\n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*](ctso-20260331xex32d1.htm)\n\n32.2**\n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*](ctso-20260331xex32d2.htm)\n\n101*\n\nThe following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (ii) Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2026 and 2025, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 and (v) Notes to Condensed Consolidated Financial Statements.\n\n104*\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n*   Filed herewith.\n\n** Furnished herewith.\n\n​\n\n​\n\n33\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n \n\n**CYTOSORBENTS CORPORATION**\n\n \n\n \n\nDated: May 13, 2026\n\nBy:\n\n/s/ Phillip P. Chan\n\n \n\n \n\nName: Phillip P. Chan\n\n \n\n \n\nTitle: Chief Executive Officer\n\n \n\n \n\n(Principal Executive Officer)\n\n​\n\n​\n\n​\n\nDated: May 13, 2026\n\nBy:\n\n/s/ Peter J. Mariani\n\n \n\n \n\nName: Peter J. Mariani\n\n \n\n \n\nTitle: Chief Financial Officer\n\n \n\n \n\n(Principal Financial and Accounting Officer)\n\n​\n\n​\n\n34"}